Optovue Corp.
Adoption of Imaging System Continues to Accelerate Around the Globe
FREMONT, Calif., Nov 13, 2008 --
Optovue, a pioneer in optical coherence tomography (OCT), announced that
the company has now shipped more than 1000 RTVue™
systems worldwide.
In just two years since its introduction, RTVue has gained rapid
acceptance by leading clinicians around the globe. RTVue is the first
and only FDA-cleared spectral domain OCT capable of imaging both the
front (cornea) and back (retina) of the eye in a single system. In
addition, RTVue offers unprecedented analytical capabilities, allowing
physicians to evaluate tissue at greater depths and with more detail
than is possible with other commercially available systems. These
functions, together with other proprietary features such as extensive
normative databases, have helped establish RTVue as a clinical and
market leader.
"When our practice considered the options for
spectral domain OCT, we concluded that RTVue offered the best
combination of performance and value," said
Lawrence Singerman, MD, a clinical professor of ophthalmology at Case
Western University and a senior physician at Retina Associates of
Cleveland, which purchased unit number 1000 along with three other
RTVues. "The system gives us the resolution we
need, together with image registration and excellent progression
mapping. Plus it is easy for technicians to operate. In short, RTVue
gives us the right package of functions for our clinical needs, at an
acceptable price."
A Strong 2008
This milestone comes at the end of a strong year for Optovue. Revenue
has increased 80 percent over 2007, fueled by adoption both in the
United States and abroad. Internationally, Optovue marked a number of
achievements this year. Most recently, the company was granted marketing
registration in China. With this clearance, Optovue now sells RTVue in
every major market in Asia.
In addition, the company established its first European operations,
based in Heidelberg, Germany. This step is part of Optovue's commitment
to provide the same high quality service to its users in that region as
the company is already known for in the United States.
"Our strong sales performance, even in the
face of much larger competitors, speaks to the quality of our technology
and our ability to meet the needs of clinicians,"
said Jay Wei, the company's CEO. "We
may be the new company in this field, but we have great depth of
experience in OCT. This combination has enabled us to bring a fresh
perspective to OCT, and to create the most innovative, versatile
technology available today."
About Optovue ( www.optovue.com)
Optovue Corp. is a privately held ophthalmic device company dedicated to
working with eye care professionals and clinical researchers to lead the
commercialization of new imaging modalities that improve diagnosis and
therapy of ocular disease. Optovue has achieved widespread market
success through a combination of unique data analysis design, a
reputation for excellent customer service, and rapid innovation of its
technology in response to physician feedback. The company is
headquartered in Fremont, CA, with European operations in Heidelberg,
Germany.
SOURCE: Optovue Corp.
Asclepius Communications
Susan Scher, 415-339-9404
[email protected]